Effect of Intravenous Zoledronic Acid on Total Knee Replacement in Patients With Symptomatic Knee Osteoarthritis and Without Severe Joint Space Narrowing: A Prespecified Secondary Analysis of a Two-Year, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Two hundred twenty-two patients with symptomatic knee osteoarthritis and without severe joint space narrowing were randomized to receive either intravenous zoledronic acid (5 mg annually, n=113) or placebo (n=109). The primary outcome of interest was the risk of total knee replacement. Secondary outcomes included the incidence of total knee replacement in the study knee, total knee replacement in the contralateral knee, and changes in knee pain scores over time. Outcomes were assessed over a mean follow-up period of seven years. Overall, the study found that zoledronic acid was not protective against total knee replacement. In fact, during the first two years, patients receiving zoledronic acid had a significantly higher risk of total knee replacement compared to placebo. However, after the trial period, the risk was similar between groups. These findings suggest that zoledronic acid is not beneficial in preventing knee replacement in this patient population and may even accelerate the need for surgery in the short term.